A large part of the pharmaceuticals traded on the Russian market in the first half of 2013 did not meet various quality standards, according to the results of testing carried out by the Federal Service on Surveillance in Healthcare (Roszdravnadzor). Out of all the products withdrawn from the market as a result of the testing, 66% (126 series) were produced domestically and 34% (65 series) were imported.
Roszdravnadzor found that in the case of foreign-produced medications, those with the highest number of complaints from consumers were manufactured by Boehringer Ingelheim Ellas A. E., Sishui Xirkang Pharmaceutical Co., Ltd. and Dr. Reddy’s Laboratories Ltd. Meanwhile, Vifiteh, Biohimic and Yodnye tekhnologii i marketing were among domestic producers that had the highest number of complaints.
Authorities have decided to withdraw 86 domestic medications and 36 imported ones. The products were checked as to their compliance in categories such as description, packaging, microbiological purity and required quantity.